Milestone Pharmaceuticals... (MIST)
1.26
0.10 (8.62%)
At close: Apr 24, 2025, 3:59 PM
1.29
2.75%
Pre-market: Apr 25, 2025, 04:57 AM EDT
8.62% (1D)
| Bid | 1.23 |
| Market Cap | 66.99M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -41.52M |
| EPS (ttm) | -0.73 |
| PE Ratio (ttm) | -1.72 |
| Forward PE | -0.88 |
| Analyst | Buy |
| Ask | 1.3 |
| Volume | 1,904,360 |
| Avg. Volume (20D) | 2,482,940 |
| Open | 1.17 |
| Previous Close | 1.16 |
| Day's Range | 1.09 - 1.26 |
| 52-Week Range | 0.63 - 2.75 |
| Beta | 1.38 |
About MIST
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and ...
Industry Biotechnology
Sector Healthcare
IPO Date May 9, 2019
Employees 33
Stock Exchange NASDAQ
Ticker Symbol MIST
Website https://www.milestonepharma.com
Analyst Forecast
According to 2 analyst ratings, the average rating for MIST stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 656.67% from the latest price.
Stock Forecasts4 weeks ago
-60.89%
Milestone Pharmaceuticals shares are trading lower...
Unlock content with
Pro Subscription
8 months ago
+2.86%
Milestone Pharmaceuticals shares are trading higher after Rodman & Renshaw initiated coverage on the stock with a Buy rating and announced a $9 price target.
